about
Oncogene-Induced Senescence: Putting the Brakes on Tumor DevelopmentStromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in miceExtending the Dynamic Range in Metabolomics Experiments by Automatic Correction of Peaks Exceeding the Detection Limit.Automated Annotation and Evaluation of In-Source Mass Spectra in GC/Atmospheric Pressure Chemical Ionization-MS-Based Metabolomics.Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaBSenescence, apoptosis and therapy--cutting the lifelines of cancer.Initiation of acute graft-versus-host disease by angiogenesis.Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.Cellular senescence and cancer treatment.Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomasB-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.Non-cell-autonomous tumor suppression: oncogene-provoked apoptosis promotes tumor cell senescence via stromal crosstalk.The Myc/macrophage tango: oncogene-induced senescence, Myc style.CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma.Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.Cellular senescence predicts treatment outcome in metastasised colorectal cancer.FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf.Genetic analysis of chemoresistance in primary murine lymphomas.The Ink4a/Arf locus operates as a regulator of the circadian clock modulating RAS activity.Senescence-associated reprogramming promotes cancer stemness.Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.Compound annotation in liquid chromatography/high-resolution mass spectrometry based metabolomics: robust adduct ion determination as a prerequisite to structure prediction in electrospray ionization mass spectra.Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma.Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.The persistent dynamic secrets of senescence.Detecting Markers of Therapy-Induced Senescence in Cancer Cells.T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy.Mouse models of human cancer.Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo.UnSASPing Senescence: Unmasking Tumor Suppression?Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast CancerBcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivoRecurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivoTargeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in MelanomaNon-invasive metastasis prognosis from plasma metabolites in stage II colorectal cancer patients: The DACHS studyThe dynamic nature of senescence in cancerThe Senescence-Stemness Alliance - A Cancer-Hijacked Regeneration Principle
P50
Q22065360-B8B63223-021C-4D65-8628-35DAB2F665D1Q27305136-B195B613-C829-4682-8CFD-59240797ACFDQ33468327-4FFB23FF-A33E-442B-A728-2D910C74489EQ33468719-E83BC5C0-9222-4B20-9EC0-188988AEE0A3Q33656653-04384825-7001-44DB-90FF-70FAF89CB6BCQ33656653-2FC7A213-A350-477E-997B-120FE77A47FFQ34187808-61E345B1-E385-4FFB-BEE6-B0139345B0AAQ34549480-C7AA1E48-B582-4F42-AADD-E22244A6953EQ35493964-8EF16503-3BA9-4A0A-948F-F49389D09C29Q36616891-D38FC5AF-FDE2-435A-AD43-C77257CA3A28Q36761564-864726B6-7AAB-424A-8C24-6D62058E2D44Q36965870-C371D3A2-A094-4724-965B-B99C0224B235Q37877162-379CAFA1-03C8-4449-A6BB-AC96E41F1694Q37948501-76A02233-C797-4632-90BC-D120A8250C86Q38793976-429E963A-FB36-447B-B7CA-5B0CF1B49282Q39349837-F4DA4E52-1172-4751-9C3E-0E00B17A2FD0Q40455172-A1813F40-A7B6-40BD-8CF9-E1345A584DDCQ42426506-7A02BF77-5F6F-404A-B51E-A9DB06B5D00CQ42636934-484A1D63-C971-479A-A778-5468C40D2695Q43422059-5BCCA12D-EFF8-46A2-A206-100D94168A33Q45943215-6FEF47E7-22F8-4B8B-B503-0953F8A574DBQ47282247-0CA41BD9-0C9B-48CA-A681-7601B292B36AQ47778719-FDB2749F-F060-44F3-9FA4-C9ABBB6B242CQ47848166-F370B8C9-32C7-4596-BD3D-B4089F8E6B6DQ50040360-BD0EB9D8-F848-4E93-A581-1F50B7351AEBQ50750868-36F6BDA5-534F-406F-BE0E-32759304C391Q51418651-1DD9D015-8039-43D4-8ACB-53BA17D3C2AEQ51544784-58AF1121-C506-42E3-8339-80123F7ACE27Q52838418-06C5F313-88E7-46A9-B8C5-4447593E434CQ52855778-9EF62D47-1E90-46E8-B606-51376FDB91E6Q52874489-3E618366-513C-453B-B259-142432D76982Q52905010-5D318BE8-08ED-434C-BE44-A38F8DC239BDQ52925669-503E544B-A004-4234-8FDF-B96AA8806EA7Q56963655-B73C82B8-FB79-4554-AFD2-E2E19AA48F0EQ64245254-25C9222C-9009-4BAC-872B-32019B3FB8B4Q73893207-2271D543-BB15-452C-91D4-2AD572953260Q81639776-DB87306F-9001-4FD1-A604-0CC0474A5C37Q88318297-DFFC8A54-7025-44FE-BA95-0879A1D3EBF0Q90606264-B3658A2A-588F-4E51-95ED-A32160915EFBQ90854400-C83C282A-D54A-498D-93F7-BAC36855672C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Clemens A Schmitt
@ast
Clemens A Schmitt
@en
Clemens A Schmitt
@es
Clemens A Schmitt
@nl
Clemens A Schmitt
@sl
type
label
Clemens A Schmitt
@ast
Clemens A Schmitt
@en
Clemens A Schmitt
@es
Clemens A Schmitt
@nl
Clemens A Schmitt
@sl
prefLabel
Clemens A Schmitt
@ast
Clemens A Schmitt
@en
Clemens A Schmitt
@es
Clemens A Schmitt
@nl
Clemens A Schmitt
@sl
P106
P31
P496
0000-0002-4731-2226